A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-12-28
Adverse events
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-04 (study day 56); relationship: not assessed
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-17 (study day 69); relationship: not assessed; serious criteria: hospitalization
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-13 (study day 157); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-08-04 (study day 209); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-10-19 (study day 285); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-24 (study day 290); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 343); relationship: not assessed
Data queries
No data queries.